Back to Directory

Tafadzwa Kasambira

Email

tafadzwa.kasambira@nih.gov

Phone

301-761-6919

Institution

NIAID, NIH

Address

DAIDS, NIAID, NIH, DHHS
5601 Fishers Lane, Rm 9B49
Rockville, MD 20852
USA

Request an Update

Affiliated Studies

IMPAACT 2049: LEAP

DAIDS Number

Research Area

Study Status

IMPAACT 2047: Radiant-Moms Plus

DAIDS Number

Research Area

Study Status

IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

Research Area

Study Status

IMPAACT 2035/HVTN 604: Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP)

DAIDS Number

Research Area

Study Status

P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) Given in Combination with an Individualized Rifampin-Resistant Tuberculosis (RR-TB) Therapy in Infants, Children and Adolescents with RR-TB Disease, Living with or without HIV

DAIDS Number

Research Area

Study Status

Closed to Follow Up

Show All